{"id":475876,"date":"2020-03-24T18:10:01","date_gmt":"2020-03-24T18:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475876"},"modified":"2020-03-24T18:10:01","modified_gmt":"2020-03-24T18:10:01","slug":"peanut-allergy-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/peanut-allergy-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_475876.html","title":{"rendered":"Peanut Allergy Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"
\"Peanut<\/a><\/p>\n
\n
“Peanut Allergy- Market Insight, Epidemiology and Market Forecast -2030”<\/div>\n<\/div>\n<\/div>\n

(Albany, US) DelveInsight launched a new report on “Peanut Allergy Market Insights, Epidemiology and Market Forecast-2030<\/a><\/span>”.<\/p>\n

DelveInsight’s “Peanut Allergy – Market Insights, Epidemiology, and Market Forecast-2030″<\/strong> report delivers an in-depth understanding of the Peanut Allergy, historical and forecasted epidemiology as well as the Peanut Allergy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the facts of the report<\/strong><\/p>\n

1. As per DelveInsight estimates, total prevalent population of Peanut Allergy in the 7MM was found to be 8,640,527 in 2017.
2. As per DelveInsight analysis, it is observed that, Japan has the least number of prevalent cases (1,548,318 for 2017) of Peanut Allergy, among the 7MM.
3. The total cases of mild and moderate to severe Peanut Allergy in the US varied as 2,341,384 and 1,153,219 respectively.<\/p>\n

Key benefits of the report<\/strong><\/p>\n

1. Peanut Allergy market report covers a descriptive overview and comprehensive insight of the Peanut Allergy epidemiology and Peanut Allergy market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Peanut Allergy market report provides insights on the current and emerging therapies.
3. Peanut Allergy market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. Peanut Allergy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Peanut Allergy market.<\/p>\n

Request for sample pages :<\/strong> https:\/\/www.delveinsight.com\/sample-request\/peanut-allergy-market<\/a><\/p>\n

“According to DelveInsight, most of the patients diagnosed with Peanut Allergy were male.”
<\/em><\/strong>
Food allergy is an abnormal response to a food triggered by the body’s immune system. There are several types of immune response to food. A peanut allergy is an allergic reaction to peanuts which occurs when the human body mistakenly identifies peanuts as harmful substances. Peanut allergy is recognized as one of the most severe food allergies due to its prevalence, persistency, and the potential severity of the allergic reaction. Although other food allergies occurring in childhood usually resolve spontaneously with age, peanut sensitivity appears early in life and often persists indefinitely.<\/p>\n

Frequently, large quantities of peanut allergens are not needed to elicit an allergic reaction- even trace levels of peanut are capable of causing a hypersensitive reaction.<\/p>\n

The symptoms of peanut allergy vary from mild to severe, from swollen lips, shortness of breath to ananaphylactic shock, which is potentially fatal.<\/p>\n

– Mild to moderate symptoms are<\/strong>: Itchy skin or hives, which can appear as small spots or largewelts, an itching or tingling sensation in or around the mouth or throat, nausea, a runny or  congested nose.<\/p>\n

– The most severe allergic reaction to peanuts is anaphylaxis, a life-threatening whole-body response to an allergen. Symptoms include impaired breathing, swelling in the throat, a sudden drop in blood pressure, pale skin or blue lips, fainting and dizziness.<\/p>\n

“According to DelveInsight, Among the EU5 countries, France had the highest prevalent population of Peanut Allergy with 614,959 cases, followed by Germany and the United Kingdom. “<\/em><\/strong><\/p>\n

The launch of the emerging therapies is expected to significantly impact Peanut Allergy treatment scenario in the upcoming years:-
Drugs covered<\/p>\n

    \n
  1. Palforzia<\/li>\n
  2. Viaskin Peanut<\/li>\n
  3. ANB020<\/li>\n
  4. Omalizumab<\/li>\n<\/ol>\n

    And many others<\/p>\n

    The key players in Peanut Allergy market are:<\/p>\n

      \n
    1. Aimmune Therapeutics<\/li>\n
    2. DBV Technologies<\/li>\n
    3. AnaptysBio<\/li>\n
    4. Genentech<\/li>\n<\/ol>\n

      And many others<\/p>\n

      Request for sample pages : https:\/\/www.delveinsight.com\/sample-request\/peanut-allergy-market<\/a><\/p>\n

      Table of contents<\/strong><\/p>\n

      1. Key Insights<\/p>\n

      2. Peanut Allergy: Market Overview at a Glance<\/p>\n

      2.1. Total Market Share (%) Distribution of Peanut Allergy in 2017<\/p>\n

      2.2. Total Market Share (%) Distribution of Peanut Allergy in 2030<\/p>\n

      3. Peanut Allergy: Disease Background and Overview<\/p>\n

      3.1.1.Introduction<\/p>\n

      3.1.2.Peanut Allergen<\/p>\n

      3.1.3.Characterization of Peanut Allergens<\/p>\n

      3.2. Clinical Presentation<\/p>\n

      3.2.1.Clinical Symptoms<\/p>\n

      3.3. Causes and Risk Factors<\/p>\n

      3.3.1.Risk Factors<\/p>\n

      3.4. Pathophysiology of Peanut Allergy<\/p>\n

      3.5. Cross-reactivity with Other Foods<\/p>\n

      3.5.1.Outgrowing Peanut Allergy<\/p>\n

      3.6. Diagnosis of Peanut Allergy<\/p>\n

      3.6.1.History, the key Diagnostic Test<\/p>\n

      3.6.2.Skin Prick Tests (SPT)<\/p>\n

      3.6.3.Serum Peanut-IgE Concentration<\/p>\n

      3.6.4.Component Testing<\/p>\n

      3.6.5.Peanut-Induced Anaphylactic Reactions<\/p>\n

      4. Epidemiology and Patient Population<\/p>\n

      4.1. Key Findings<\/p>\n

      5. Total Prevalent Population of Peanut Allergy in 7MM<\/p>\n

      6. United States Epidemiology<\/p>\n

      6.1. Assumptions and Rationale<\/p>\n

      6.2. Total Prevalent Population of Peanut Allergy in the United States (2017–2030)<\/p>\n

      6.3. Gender-Specific Prevalent Population of Peanut Allergy in the United States (2017–2030)<\/p>\n

      6.4. Age-Specific Prevalent Population of Peanut Allergy in the United States (2017–2030)<\/p>\n

      6.5. Severity–Specific Prevalent Population of Peanut Allergy in the United States (2017–2030)<\/p>\n

      7. EU5 Epidemiology<\/p>\n

      7.1. Germany Epidemiology<\/p>\n

      7.1.1.Assumptions and Rationale<\/p>\n

      7.1.2.Total Prevalent Population of Peanut Allergy in Germany (2017–2030)<\/p>\n

      7.1.3.Gender-Specific Prevalent Population of Peanut Allergy in Germany (2017–2030)<\/p>\n

      7.1.4.Age-Specific Prevalent Population of Peanut Allergy in Germany (2017–2030)<\/p>\n

      7.1.5.Severity–Specific Prevalent Population of Peanut Allergy in Germany (2017–2030)<\/p>\n

      7.2. France Epidemiology<\/p>\n

      7.2.1.Assumptions and rationale<\/p>\n

      7.2.2.Total Prevalent Population of Peanut Allergy in France (2017–2030)<\/p>\n

      7.2.3.Gender-Specific Prevalent Population of Peanut Allergy in France (2017–2030)<\/p>\n

      7.2.4.Age-Specific Prevalent Population of Peanut Allergy in France (2017–2030)<\/p>\n

      7.2.5.Severity–Specific Prevalent Population of Peanut Allergy in France (2017–2030)<\/p>\n

      7.3. Italy Epidemiology<\/p>\n

      7.3.1.Assumptions and Rationale<\/p>\n

      7.3.2.Total Prevalent Population of Peanut Allergy in Italy (2017–2030)<\/p>\n

      7.3.3.Gender-Specific Prevalent Population of Peanut Allergy in Italy (2017–2030)<\/p>\n

      7.3.4.Age-Specific Prevalent Population of Peanut Allergy in Italy (2017–2030)<\/p>\n

      7.3.5.Severity–Specific Prevalent Population of Peanut Allergy in Italy (2017–2030)<\/p>\n

      7.4. Spain Epidemiology<\/p>\n

      7.4.1.Assumptions and Rationale<\/p>\n

      7.4.2.Total Prevalent Population of Peanut Allergy in Spain (2017–2030)<\/p>\n

      7.4.3.Gender-Specific Prevalent Population of Peanut Allergy in Spain (2017–2030)<\/p>\n

      7.4.4.Age-Specific Prevalent Population of Peanut Allergy in Spain (2017–2030)<\/p>\n

      7.4.5.Severity–Specific Prevalent Population of Peanut Allergy in Spain (2017–2030)<\/p>\n

      7.5. United Kingdom Epidemiology<\/p>\n

      7.5.1.Assumptions and Rationale<\/p>\n

      7.5.2.Total Prevalent Population of Peanut Allergy in the UK (2017–2030)<\/p>\n

      7.5.3.Gender-Specific Prevalent Population of Peanut Allergy in the UK (2017–2030)<\/p>\n

      7.5.4.Age-Specific Prevalent Population of Peanut Allergy in the UK (2017–2030)<\/p>\n

      7.5.5.Severity–Specific Prevalent Population of Peanut Allergy in the UK (2017–2030)<\/p>\n

      8. Japan Epidemiology<\/p>\n

      8.1.1.Assumptions and Rationale<\/p>\n

      8.1.2.Total Prevalent Population of Peanut Allergy in Japan (2017–2030)<\/p>\n

      8.1.3.Gender-Specific Prevalent Population of Peanut Allergy in Japan (2017–2030)<\/p>\n

      8.1.4.Age-Specific Prevalent Population of Peanut Allergy in Japan (2017–2030)<\/p>\n

      8.1.5.Severity–Specific Prevalent Population of Peanut Allergy in Japan (2017–2030)<\/p>\n

      9. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

      9.1. Primary Prevention<\/p>\n

      9.2. Management<\/p>\n

      9.3. Oral Immunotherapy<\/p>\n

      9.4. Treatment Guidelines<\/p>\n

      9.4.1.Practice Guidelines for Peanut Allergies<\/p>\n

      10. Unmet Needs<\/p>\n

      11. Marketed Therapies<\/p>\n

      11.1. Palforzia: Aimmune Therapeutics<\/p>\n

      11.1.1.Product Description<\/p>\n

      11.1.2.Mechanism of Action<\/p>\n

      11.1.3.Regulatory Milestones<\/p>\n

      11.1.4.Safety and Efficacy<\/p>\n

      11.1.5.Clinical Trial Information<\/p>\n

      11.1.6.Advantages and Disadvantages<\/p>\n

      11.1.7.Product Profile<\/p>\n

      12. Emerging Therapies<\/p>\n

      12.1. Key Cross Competition<\/p>\n

      12.2. Viaskin Peanut: DBV Technologies<\/p>\n

      12.2.1. Product Description<\/p>\n

      12.2.2. Other Developmental Activities<\/p>\n

      12.2.3. Clinical Development<\/p>\n

      12.2.4. Safety and Efficacy<\/p>\n

      12.2.5. Product Profile<\/p>\n

      12.3. ANB020: AnaptysBio<\/p>\n

      12.3.1. Drug Description<\/p>\n

      12.3.2. Other Developmental Activities<\/p>\n

      12.3.3. Clinical Development<\/p>\n

      12.3.4. Safety and Efficacy<\/p>\n

      12.3.5. Product Profile<\/p>\n

      12.4. Omalizumab: Genentech<\/p>\n

      12.4.1. Drug Description<\/p>\n

      12.4.2. Other Developmental Activities<\/p>\n

      12.4.3. Clinical Development<\/p>\n

      12.4.4. Safety and Efficacy<\/p>\n

      12.4.5. Product Profile<\/p>\n

      Drug list continued..<\/p>\n

      13. Peanut Allergy: 7MM Market Analysis<\/p>\n

      13.1. Key Findings<\/p>\n

      13.2. Market Size of Peanut Allergy in 7MM (2017–2030)<\/p>\n

      14. United States: Market Outlook<\/p>\n

      14.1. United States Market Size<\/p>\n

      14.1.1. The total market size of Peanut Allergy<\/p>\n

      14.1.2. Market Size of Peanut Allergy by Therapies in the US<\/p>\n

      15. EU-5 countries: Market Outlook<\/p>\n

      15.1. Germany Market Size<\/p>\n

      15.1.1. The total market size of Peanut Allergy<\/p>\n

      15.1.2. Market Size of Peanut Allergy by therapies in Germany<\/p>\n

      15.2. France Market Size<\/p>\n

      15.2.1. The total market size of Peanut Allergy<\/p>\n

      15.2.2. Market Size of Peanut Allergy by therapies in France<\/p>\n

      15.3. Italy Market Size<\/p>\n

      15.3.1. The total market size of Peanut Allergy<\/p>\n

      15.3.2. Market Size of Peanut Allergy by therapies in Italy<\/p>\n

      15.4. Spain Market Size<\/p>\n

      15.4.1. The total market size of Peanut Allergy<\/p>\n

      15.4.2. Market Size of Peanut Allergy by therapies in Spain<\/p>\n

      15.5. United Kingdom Market Size<\/p>\n

      15.5.1. The total market size of Peanut Allergy<\/p>\n

      15.5.2. Market Size of Peanut Allergy by therapies in the UK<\/p>\n

      16. Japan Market Outlook<\/p>\n

      16.1. Japan Market Size<\/p>\n

      16.1.1. The total market size of Peanut Allergy<\/p>\n

      16.1.2. Market Size of Peanut Allergy by therapies in Japan<\/p>\n

      17. Market Drivers<\/p>\n

      18. Market Barriers<\/p>\n

      19. Appendix<\/p>\n

      19.1. Report Methodology<\/p>\n

      20. DelveInsight Capabilities<\/p>\n

      21. Disclaimer<\/p>\n

      22. About DelveInsight<\/p>\n

      Related Reports: <\/strong><\/p>\n

      Peanut Allergy – Pipeline Insights, 2020<\/strong><\/a><\/p>\n

      The Peanut Allergy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Peanut Allergy across the complete product development cycle, including all clinical and nonclinical stages.<\/p>\n

      Peanut Allergy – Epidemiology Forecast to 2030<\/a><\/strong><\/p>\n

      The Peanut Allergy epidemiology covered in the report provides historical as well as forecasted Peanut Allergy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.<\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Ankit Nigam
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> +919650213330
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Albany
      State:<\/strong> New York
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      “Peanut Allergy- Market Insight, Epidemiology and Market Forecast -2030” (Albany, US) DelveInsight launched a new report on “Peanut Allergy Market Insights, Epidemiology and Market Forecast-2030”. DelveInsight’s “Peanut Allergy – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,423,403,404],"tags":[],"class_list":["post-475876","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475876"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475876\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}